Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

• Understand the rationale behind the updated definition of control for CRSwNP as proposed by EPOS EUFOREA 2024, and how it differs from the EPOS 2020 definition
• Recognize the importance of patient-reported outcomes and the absence of clinically relevant nasal symptoms in assessing the control of CRSwNP
• Comprehend the necessity for clear definitions of disease control and severity to effectively select patients for biologic treatments and evaluate treatment efficacy

Prof. Hellings and Prof. Corso discuss the updated definition of control for CRSwNP from EPOS 2020 to EUFOREA 2024. The new definition emphasizes on patient-reported control and absence of significant nasal symptoms, reflecting current clinical and scientific consensus. This change aims to better identify patients for biologic treatments and assess treatment efficacy, focusing on symptoms and quality of life rather than endoscopic findings. The new criteria are considered practical, understandable, and essential for current medical practice.